The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Corporate Majority | Acquired

About Motus

Motus offers logistics and operational management services for physical and E-Commerce stores.On March 29th, 2022, Grupo GPS acquired a majority stake in Motus. Terms of the transaction were not disclosed.

Motus Headquarter Location

R Paulo Licio Rizzo, 176

Sao Paulo, 05594,


+55 (11) 95336-6740

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Motus News

Motus GI Reports First Quarter 2022 Financial Results and Provides Business Update

May 12, 2022

Ft. Lauderdale, Florida, UNITED STATES Pure-Vu EVS approved for use at 11 hospitals since product launch commenced in March 2022; with strong procedural volumes and significant positive feedback Expansion of US commercial footprint ahead of schedule, with additional investments planned throughout 2022 Designing a large, multi-center trial as part of the strategy to secure reimbursement for the Pure-Vu EVS System for certain outpatient colonoscopies FORT LAUDERDALE, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the first quarter ended March 31, 2022, and provided a corporate update. “As we guided at the end of March, our first quarter revenues were impacted by both the surge of Omicron in the US and associated staffing shortages at hospitals, as well as the sunsetting of Pure-Vu Gen2 and initiating our first commercial shipments of Pure-Vu EVS to US hospitals,” commented Tim Moran, Chief Executive Officer. “During the first quarter, in addition to receiving FDA clearance for the Pure-Vu EVS, we accelerated the expansion of our sales organization as we look to capitalize on what we believe is the right technology to drive broader market adoption. Moreover, we continue to receive positive feedback from both physicians and staff regarding the advancements offered by the all-new Pure-Vu EVS. While it’s early into the commercial launch, we are excited to see physicians performing more procedures than before and, based on the simplicity of the new device, we believe accounts are becoming independent more rapidly. These are important initial indicators that we expect will lead to sustainable, quarterly revenue growth in the US market.” “It was just six weeks ago that I forecasted we’d have Pure-Vu EVS placed in approximately 12 sites in the near-term. I’m pleased to report that midway through the second quarter, we’re well on track to far exceed that expectation, having Pure-Vu EVS approved for use at 11 hospital accounts since March,” commented Mr. Moran. First Quarter and Recent Business Highlights Received 510(k) clearance from the U.S. FDA for the Pure-Vu EVS System in mid-February 2022. March represented a key transitional period for the Company as it completed the sunsetting activities of Pure-Vu Gen2 and began shipments of the all-new Pure-Vu EVS to U.S. customers. Company on track with initial guidance of placing Pure-Vu EVS at first 12 sites Clinical Data Generation Completed enrollment in the European Union (EU) study of the Pure-Vu System, which is evaluating the clinical outcomes in patients with a history of poor bowel preparation using both a low volume preparation with limited diet restrictions and the Pure-Vu System. The Company expects to announce topline data from the study at a leading scientific conference in May 2022. Topline data from the investigator-initiated EU clinical study exploring limited bowel prep for CRC screening at two European health centers expected to be presented during Digestive Disease Week 2022 in May 2022. Outpatient Reimbursement Strategy Continue advancing a multi-pronged strategy to secure reimbursement for the Pure-Vu System procedure by both private and public payers that could accelerate use for certain outpatient colonoscopies, within a market representing approximately 4.7 million targeted outpatient procedures per year. Actively designing a large, multi-center trial that may generate clinical and economic endpoints in the outpatient segment that will support applications seeking reimbursement of the Pure-Vu System. Product Innovation Initiated a project to add Upper GI capabilities to the new Pure-Vu EVS platform. Upper GI bleeds occurred in the U.S. at a rate of approximately 400,000 cases per year in 2019, according to iData Research Inc. The existence of blood and blood clots in these patients can impair a physician’s view, making it difficult to identify the bleed source. Motus believes removing adherent blood clots from the field of view is a significant need in allowing a physician the ability to identify and treat the bleed source. The mortality rate of this condition can reach up to approximately 10%, as noted in Thad Wilkins, MD, et al., American Family Physician (2012). Key enhancements expected to be featured in the Pure-Vu EVS include a large and powerful suction channel, more efficient irrigation jets, and a smaller profile distal tip that offers enhanced flexibility during insertion. Financial Results for the First Quarter Ended March 31, 2022 The Company reported revenue of $20,000 for the first quarter 2022, compared to $51,000 for the same period last year. The impact of both the Omicron variant early in the first quarter and the controlled phase-out of the Gen 2 System ahead of the EVS launch later in the quarter significantly affected our first quarter results. The Company believes that these specific factors will be less impactful in the second quarter of 2022 and beyond. For the three months ended March 31, 2022, the Company reported a net loss attributable to common sharholders of $4.8 million, or $0.09 per basic and diluted share, compared to a net loss attributable to common shareholders of $10.8 million, or $0.25 per basic and diluted share, for the same period last year, which included the impact of a non-cash “deemed dividend from warrant issuance” of $6.1 million. During the first quarter 2022, net cash used in operating activities and for the purchase of fixed assets was $5.2 million as compared to $4.7 million for the same period of 2021. First quarter 2022 cash expenditures included certain one-time annual outflows associated with compliance and corporate matters, totaling approximately $1.8 million, which is not expected to recur in future quarters this year. The Company reported $20.3 million in cash and cash equivalents as of March 31, 2022. This balance includes the fully funded $12.0 million credit facility with Kreos Capital. The Company’s current cash balance allows it to continue executing on its upcoming catalysts and is expected to meet overall anticipated cash needs into Q1 2023. Motus GI Holdings, Inc. and Subsidiaries Condensed Consolidated Balance Sheets Highlights (unaudited, in thousands)

  • Where is Motus's headquarters?

    Motus's headquarters is located at R Paulo Licio Rizzo, 176, Sao Paulo.

  • What is Motus's latest funding round?

    Motus's latest funding round is Corporate Majority.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.